| Drug Type Small molecule drug | 
| Synonyms BMS 688521, BMS688521 | 
| Target | 
| Action antagonists | 
| Mechanism ITGAL&ITGB2 antagonists(Integrin alpha-L/beta-2 (LFA-1) antagonists) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhasePendingPreclinical | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC26H19Cl2N5O4 | 
| InChIKeyLILGMDXLRPEBNH-HFZDXXHNSA-N | 
| CAS Registry893397-44-9 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Familial Hypersensitivity Pneumonitis | Preclinical | United Kingdom  | 13 May 2010 | 





